Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to assess safety,
tolerability and pharmacokinetics and to explore efficacy of IV infusion of 10 µg/kg/day and
30 µg/kg/day serelaxin for 48 hours compared to placebo, when added to the standard therapy,
in approximately 45 Japanese AHF patients.